Spots Global Cancer Trial Database for Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors
Official Title: A Phase Ib, Multicenter, Open-label, Dose-finding Study of Patupilone Administered Intravenously Every 3 Weeks in Combination With Carboplatin AUC 6 in Adult Patients With Advanced Solid Tumors
Study ID: NCT00426582
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carboplatin
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Norwalk Hospital, Norwalk, Connecticut, United States
Associates in Oncology, Rockville, Maryland, United States
Wertz Clinical Cancer Center (Wayne State University), Detroit, Michigan, United States
Siteman Cancer Center (Washington University School of Medicine), Saint Louis, Missouri, United States
Cancer Research and Treatment Center (University of New Mexico), Albuquerque, New Mexico, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmeceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
